INFUSYSTEM HOLDINGS, INC (INFU) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Win.
59/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 7 wins, 5 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseINFU / S&P 4.55% / 15.20% |
LoseINFU / S&P 2.47% / 15.00% |
WinINFU / S&P 73.91% / 50.40% |
| 2026-Q12/3 |
WinINFU / S&P 2.90% / -4.33% |
LoseINFU / S&P 3.50% / 11.30% |
WinINFU / S&P 164.29% / 27.70% |
| 2025-Q41/3 |
LoseINFU / S&P -13.42% / 2.65% |
LoseINFU / S&P 6.36% / 9.00% |
WinINFU / S&P 210.00% / 13.40% |
| 2025-Q33/3 |
WinINFU / S&P 66.03% / 8.12% |
WinINFU / S&P 6.23% / 4.61% |
WinINFU / S&P 333.33% / 13.45% |
| 2025-Q23/3 |
WinINFU / S&P 15.99% / 10.94% |
WinINFU / S&P 8.13% / 4.83% |
WinINFU / S&P 2200.00% / 10.63% |
| 2025-Q11/3 |
LoseINFU / S&P -36.33% / -4.27% |
WinINFU / S&P 7.98% / 4.98% |
LoseINFU / S&P INFU unavailable / 10.57% |
| 2024-Q43/3 |
WinINFU / S&P 26.12% / 2.41% |
WinINFU / S&P 7.22% / 5.25% |
WinINFU / S&P 233.33% / 6.15% |
| 2024-Q32/3 |
LoseINFU / S&P -1.90% / 5.89% |
WinINFU / S&P 8.09% / 5.89% |
WinINFU / S&P 100.00% / 6.11% |
| 2024-Q21/3 |
LoseINFU / S&P -20.30% / 4.28% |
WinINFU / S&P 9.44% / 5.38% |
LoseINFU / S&P -50.00% / 5.12% |
| 2024-Q11/3 |
LoseINFU / S&P -18.69% / 10.56% |
WinINFU / S&P 12.23% / 5.71% |
LoseINFU / S&P -100.00% / 5.59% |
| 2023-Q41/3 |
LoseINFU / S&P 9.34% / 11.69% |
WinINFU / S&P 14.44% / 6.81% |
LoseINFU / S&P -400.00% / 7.78% |
| 2023-Q32/3 |
WinINFU / S&P 0.10% / -3.27% |
WinINFU / S&P 14.16% / 7.52% |
LoseINFU / S&P -864691128455135360.00% / -5.03% |
| 2023-Q22/3 |
WinINFU / S&P 24.26% / 8.74% |
WinINFU / S&P 10.59% / 9.50% |
LoseINFU / S&P -150.00% / -8.57% |
| 2023-Q10/3 |
LoseINFU / S&P -10.71% / 7.50% |
LoseINFU / S&P 8.44% / 10.77% |
LoseINFU / S&P -200.00% / -15.69% |
| 2022-Q41/3 |
WinINFU / S&P 24.18% / 7.56% |
LoseINFU / S&P 7.36% / 11.88% |
LoseINFU / S&P -116.67% / -17.99% |
| 2022-Q30/3 |
LoseINFU / S&P -27.41% / -4.88% |
LoseINFU / S&P 6.99% / 13.47% |
LoseINFU / S&P -100.00% / -1.41% |
| 2022-Q21/3 |
WinINFU / S&P -1.73% / -16.10% |
LoseINFU / S&P 7.82% / 13.71% |
LoseINFU / S&P -105.71% / 11.04% |
| 2022-Q10/3 |
LoseINFU / S&P -42.45% / -4.60% |
LoseINFU / S&P 4.37% / 15.97% |
LoseINFU / S&P -98.82% / 42.23% |
| 2021-Q41/3 |
WinINFU / S&P 30.70% / 11.03% |
LoseINFU / S&P 5.13% / 15.00% |
LoseINFU / S&P -92.50% / 96.40% |
| 2021-Q30/3 |
LoseINFU / S&P -37.33% / 0.58% |
LoseINFU / S&P 6.55% / 10.77% |
LoseINFU / S&P 54.29% / 69.42% |
| 2021-Q22/3 |
LoseINFU / S&P 2.11% / 8.55% |
WinINFU / S&P 9.24% / 6.58% |
WinINFU / S&P 169.23% / 51.81% |
| 2021-Q13/3 |
WinINFU / S&P 8.41% / 6.17% |
WinINFU / S&P 18.73% / -1.06% |
WinINFU / S&P 844.44% / 7.39% |
| 2020-Q43/3 |
WinINFU / S&P 46.49% / 12.15% |
WinINFU / S&P 20.06% / -3.72% |
WinINFU / S&P 1233.33% / -33.42% |
| 2020-Q33/3 |
WinINFU / S&P 11.09% / 8.93% |
WinINFU / S&P 50.71% / -2.04% |
WinINFU / S&P 3400.00% / -27.10% |
| 2020-Q22/3 |
WinINFU / S&P 35.92% / 20.54% |
WinINFU / S&P 106.04% / -0.46% |
LoseINFU / S&P -471.43% / -27.11% |
| 2020-Q12/3 |
WinINFU / S&P -0.47% / -19.60% |
WinINFU / S&P 216.56% / 3.47% |
LoseINFU / S&P -181.82% / -14.75% |
| 2019-Q42/3 |
WinINFU / S&P 61.25% / 9.07% |
WinINFU / S&P 668.57% / 5.36% |
LoseINFU / S&P -220.00% / 2.99% |
| 2019-Q32/3 |
WinINFU / S&P 23.02% / 1.70% |
WinINFU / S&P 504.25% / 5.02% |
LoseINFU / S&P -101.20% / 0.21% |
| 2019-Q21/3 |
LoseINFU / S&P -14.17% / 4.30% |
WinINFU / S&P 352.81% / 6.64% |
LoseINFU / S&P -91.36% / 8.65% |
| 2019-Q12/3 |
WinINFU / S&P 45.64% / 13.65% |
WinINFU / S&P 179.80% / 8.12% |
LoseINFU / S&P -86.90% / 14.29% |
| 2018-Q41/3 |
WinINFU / S&P 5.85% / -13.52% |
LoseINFU / S&P 5.62% / 9.05% |
LoseINFU / S&P -94.57% / 18.23% |
| 2018-Q31/3 |
LoseINFU / S&P -8.45% / 7.71% |
LoseINFU / S&P -56.47% / 10.21% |
WinINFU / S&P 453.33% / 19.06% |
| 2018-Q22/3 |
WinINFU / S&P 22.41% / 3.43% |
LoseINFU / S&P -74.91% / 9.03% |
WinINFU / S&P 478.57% / 14.46% |
| 2018-Q12/3 |
WinINFU / S&P 26.09% / -0.76% |
LoseINFU / S&P -82.57% / 7.68% |
WinINFU / S&P 950.00% / 12.46% |
| 2017-Q42/3 |
WinINFU / S&P 12.20% / 6.64% |
LoseINFU / S&P -85.83% / 7.03% |
WinINFU / S&P 9100.00% / 13.82% |
| 2017-Q31/3 |
WinINFU / S&P 17.14% / 4.48% |
LoseINFU / S&P -67.11% / 5.68% |
LoseINFU / S&P -314.29% / 17.57% |
| 2017-Q20/3 |
LoseINFU / S&P -23.91% / 3.09% |
LoseINFU / S&P -47.23% / 4.83% |
LoseINFU / S&P -216.67% / 17.74% |
| 2017-Q10/3 |
LoseINFU / S&P -9.80% / 6.07% |
LoseINFU / S&P -24.54% / 3.67% |
LoseINFU / S&P -157.14% / 13.32% |
| 2016-Q40/3 |
LoseINFU / S&P -8.27% / 3.82% |
LoseINFU / S&P -0.64% / 2.09% |
LoseINFU / S&P -108.33% / 7.05% |
| 2016-Q32/3 |
WinINFU / S&P 6.92% / 3.85% |
WinINFU / S&P 5.72% / 0.20% |
LoseINFU / S&P -36.36% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | INFU total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 11.87% | 20.78% |
| Annualized return | 11.87% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | INFU total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -16.31% | 83.14% |
| Annualized return | -3.50% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | INFU total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 323.16% | 319.30% |
| Annualized return | 15.52% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Profound Medical Corp. (PROF) | $0.206B | -7.37 |